Skip to main content

Home/ MaRS/ Group items tagged offices

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Assunta Krehl

Pershing Square Announces Another Prominent Canadian Business Leader to Join the Nomine... - 0 views

www.newswire.ca/...nominees-for-management-change

Anthony Melman Cogniciti

shared by Assunta Krehl on 28 Feb 12 - No Cached
  • Assunta Krehl on 28 Feb 12
     
    Pershing Square Capital Management, L.P. announced that Paul Haggis, one of Canada's most respected business leaders, has agreed to join the Nominees for Management Change. Dr. Anthony R. Melman, 64, is Chairman and Chief Executive Officer of Nevele Inc. Dr Melman is also the Chair of the Board of Directors Dr. Melman pf Cogniciti Inc., a for-profit joint venture created by Baycrest and MaRS Discovery District.
Miguel Amante

MaRS centre signs commercialization agreement - 0 views

www.canhealth.com/News1467.html

MaRS Innovation life sciences

shared by Miguel Amante on 24 Aug 10 - Cached
  • Miguel Amante on 24 Aug 10
     
    MaRS Innovation (MI) has signed a co-funding agreement with the Johnson & Johnson Corporate Office of Science and Technology to capitalize and accelerate the use of Toronto-based life-sciences technologies during the early stages of pharmaceutical and medical device development.
Miguel Amante

Turning ideas into businesses - theVARSITY.ca - August 24, 2010 - 0 views

thevarsity.ca/32039

clients_tenants commercialization innovation MaRS Innovation IPO

shared by Miguel Amante on 25 Aug 10 - Cached
  • Miguel Amante on 25 Aug 10
     
    The Varsity looks at the work of the Innovations and Partnerships Office, located in the MaRS Centre.
kathryn mars

The NIH: An Attractive Partner for Collaboration - 0 views

www.slideshare.net/...rtner-for-collaboration-344140

technology health collaboration

shared by kathryn mars on 19 Feb 09 - Cached
  • kathryn mars on 19 Feb 09
     
    The NIH Partner Collaboration slideshow from the MaRS Best Practices event. Speaker/Presenter: Mukul Ranjan, Ph.D, Office of Technology Development, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
Assunta Krehl

CNW Group | CNW GROUP - MEDIA DAYBOOK | CNW Daybook for Friday, June 5, 2009 - 0 views

www.newswire.ca/...c3469.html

Ontario

shared by Assunta Krehl on 10 Aug 09 - Cached
  • Assunta Krehl on 10 Aug 09
     
    Media advisory that Dr. Williams Ontarios Chief Medical Officer of Health will be providing an update regarding H1N1 flu virus.
Assunta Krehl

reportonbusiness.com: THE COMPANY: INFONAUT INC.: Charting the right course through an ... - 0 views

www.theglobeandmail.com/...Business

Infonaut software

shared by Assunta Krehl on 04 May 09 - Cached
  • Toronto, where a small firm is using 21st-century software to create maps with similar goals - the containment of disease - by showing infection patterns that can be understood at a glance.
  • Toronto, where a small firm is using 21st-century software to create maps with similar goals - the containment of disease - by showing infection patterns that can be understood at a glance.
  • INFONAUT INC
  • ...15 more annotations...
  • Infonaut Inc. chief executive officer Niall Wallace and his partner, chief operating officer Matt McPherson, both former IT consultants for the Ontario government, created the company after helping to craft some of the recommendations that resulted from the SARS outbreak of 2003. They understood the value of visually represented, real-time infection data, and left government to set up Infonaut to develop that technology.
  • Infonaut has created three software products that turn infection information into maps. All are being tested in pilot projects and will soon be marketed commercially.
  • One, called Infection Watch Live, is now taking data gathered at 14 hospital emergency rooms in eastern Ontario and using it to create publicly accessible maps that show exactly where in the region cases of influenza and gastrointestinal diseases are active.
  • This complex mapping can help monitor and stop the spread of C. difficile and other superbugs.
  • The third product, called Regional Watch Live, generates maps and reports for regional health professionals by merging lab test results with a range of other information.
  • There's nothing wrong with Infonaut using the H1N1 flu outbreak to gain exposure, as long as the company is careful in the tone it takes, said John Lute, president of Toronto communications firm Lute and Co.
  • On the other hand, it will clearly create an opportunity if Infonaut can increase its profile, "which helps it to get its story out, which helps it to get investors, which helps it to grow.
  • Infonaut should ensure that its message is understated and that the company is not an "ambulance chaser," Mr. Lute said
  • But the company does need to give straightforward information about how its products might help mitigate an outbreak in the future, and not exaggerate its promises, she said. In particular, it needs to be upfront about the state of its pilot tests and include details of when full versions of its products will be available. It also must explain how much funding they will need to get there, Ms. Wilcox said.
  • With Infonaut, there seems to be no question that there is a public gain, he said. "If it is just an opportunistic attempt to cash in on the misfortune of others, that tends to play badly. Where a company has something that can be tied to the public interest, such as in this case ... it is very low-risk."
  • He suggests that Infonaut make good use of its pilot test partners, such as the counties in eastern Ontario that are testing the Infection Watch Live system.
  • the company should forestall any concerns over privacy issues by spelling out how it ensures data on individuals are kept confidential.
  • There's nothing wrong with using the current concerns over H1N1 flu to gain exposure, as long as Infonaut is careful about taking a calm and respectful tone to its marketing and publicity.
  • Make sure to present straightforward information about how the company's products might help mitigate an outbreak in the future, but do not exaggerate promises. Be upfront about the state of pilot tests, the timelines to get the software to market, and how much funding will be needed to go to full commercialization. Use respected third-party partners to endorse the products, a move that will give the company more credibility. If there are privacy concerns, spell them out and detail how they are being addressed.
  • The problem Build a market for a unique infection mapping system without appearing to exploit the flu outbreak The plan: Use a subtle approach and be upfront with the state of development of the software products The payoff: Higher awareness among potential customers and an expanded market
  • Assunta Krehl on 04 May 09
     
    Using 21st-century Infonaut is using software to create maps - the containment of disease - by showing infection patterns that can be understood at a glance.
Assunta Krehl

CNW Group | ONTARIO MINISTRY OF HEALTH AND LONG-TERM CARE | Media Advisory - Ontario Hu... - 0 views

www.newswire.ca/...c6945.html

Ontario

shared by Assunta Krehl on 10 Aug 09 - Cached
  • MaRs Centre Auditorium, Lower Level 101 College Street Toronto
  • Assunta Krehl on 10 Aug 09
     
    Media advisory that Dr. Williams Ontarios Chief Medical Officer of Health will be providing an update regarding H1N1 flu virus.
Assunta Krehl

Daryl Copeland to Speak at MaRS Discovery District - Guerrilla Diplomacy - February 1, ... - 0 views

www.guerrilladiplomacy.com/...eak-at-mars-discovery-district

events

shared by Assunta Krehl on 12 Feb 10 - Cached
  • Assunta Krehl on 12 Feb 10
     
    Daryl Copeland will be speaking at MaRS, at 2:00PM on the 29th of January at the offices of the McLaughlin-Rotman Centre for Global Health on the 4th floor.
Assunta Krehl

Busy Week - Kelvin Young Photography - January 25, 2010 - 1 views

kelvinyoung.wordpress.com/...busy-week-2

marketing advertising Advertising Week 2010 events

shared by Assunta Krehl on 01 Feb 10 - Cached
  • Assunta Krehl on 01 Feb 10
     
    Kevin Young, sent by the Cabinet Office, blogs about his experience about taking photos at the MaRS Centre during Advertising Week 2010.
Cathy Bogaart

Mumbai office lunches come to Canada - The Globe and Mail, January 4, 2011 - 0 views

www.theglobeandmail.com/...article1857595

social innovation social entrepreneurship clients clients & tenants tiffinday

shared by Cathy Bogaart on 05 Jan 11 - No Cached
  • Cathy Bogaart on 05 Jan 11
     
    The Globe and Mail profiles Seema Pabari of Tiffinday, a vegan-Indian lunchtime meal delivery service. Tiffinday is a Toronto start-up and a MaRS client in our social innovation practice.
Assunta Krehl

CIX Announces Partnership with the Government of Canada to Help Digital and ICT Start U... - 0 views

www.aurpcanada.ca/blog

The Canadian Innovation Exchange CIX MaRS Centre information and communication technologies innovation

shared by Assunta Krehl on 29 Sep 11 - No Cached
  • Assunta Krehl on 29 Sep 11
     
    As stated in Aurp Canada's blog "The Canadian Innovation Exchange (CIX) has partnered with the Government of Canada, through its Canadian Trade Commissioner Service office in San Francisco-Silicon Valley, to announce a prestigious development opportunity for Canadian companies working in Information and Communication Technology and Digital Media." The CIX Top 20 will take place on December 1st, 2011 at the MaRS Centre.
Sarah Hickman

MaRS Discovery District - Recommended Resources - Global Market Reports - VHA Research ... - 0 views

www.marsdd.com/...VHA-Research-Series.html

health care & life sciences marketing market research

shared by Sarah Hickman on 15 Oct 09 - No Cached
  • Sarah Hickman on 15 Oct 09
     
    "The United States spends more on health care-related research and development than any other country. In 2003, it was estimated that the Federal government alone spent over $26 billion. Pharmaceutical companies, device manufacturers and other private companies invested over $10 billion more. At its best, the American health care system is capable of delivering care unsurpassed anywhere else in the world. Yet, a 1999 Institute of Medicine study estimated that as many as 98,000 Americans die each year from hospital related medical errors. A recent study by the Rand Corporation (a non-profit think tank) concluded that less than 50 percent of encounters with doctors and hospitals resulted in optimal, evidence-based treatment. Studies show that as many as 42 million Americans - almost 15 percent of the population - lack health care insurance. Surveys reveal that patients do not feel they have adequate information about their conditions, and that their experience with health care ranks below that of most other sectors, in fact below that of the post office. In the aggregate, the country is spending nearly $2 trillion on health care, and yet the nation's health care system does not meet acceptable thresholds for safety, quality, access or cost. In 2005, VHA Health Foundation's board of directors sought to better understand the reasons behind this paradox. The foundation commissioned Larry Keeley and his associates at Doblin Inc. to apply the rigorous analytical methods that are used in their evaluation of other American industries and companies. The project set out to discover when, where and how innovation was taking place in health care. It also sought to identify organizations that were developing model innovation processes, and to explore where opportunities for successful innovation might lay."
Assunta Krehl

Test-tube industry - Canadian Business - 0 views

www.canadianbusiness.com/...article.jsp

MaRS MDS Sciex John Evans Calvin Stiller Kenneth Knox Eli Lilly Joseph Rotman Lawrence Bloomberg

shared by Assunta Krehl on 27 Aug 09 - No Cached
  • For Dr. John Evans, growing a strong biotechnology industry is much the same: cities must provide a nurturing environment where science and business can thrive together.
  • That's why Evans, former president of the University of Toronto and current chairman of Torstar Corp., is spearheading the $345-million Medical and Related Science initiative, or MaRS--a petri dish of sorts for commercializing science research. "A lot of intellectual property is being commercialized outside Canada," says Evans. "I think we've been slow in realizing just how important technology developments are to the economic future of the country. MaRS is an attempt to give this a kick into a higher gear." The centrepiece of the MaRS plan, which will officially launch May 12, is a 1.3-million-square-foot, five-building complex in downtown Toronto that will provide office and lab space for small and medium-size companies and incubators, including the not-for-profit Toronto Biotechnology Commercialization Centre. While Evans is reluctant to limit its scope, MaRS will generally focus on health-related technologies, from new drugs and genetic treatments to medical devices and imaging software. Branded a "convergence centre," it will also house a careful mix of support services: intellectual property lawyers, accountants, marketing experts, government funding organizations and venture capital financiers. Plus, start-ups will have access to all the latest equipment on site. For instance, MaRS is in talks with MDS Sciex to supply mass spectrometers, used in proteomics research.
  • But MaRS will be more than just a New Economy real estate development. Evans's intention is to funnel tenants' rent money into services--such as entrepreneurship seminars and angel-matching programs--that MaRS will offer to the broader biotech community. That's why MaRS's location is key: the centre will be built in the heart of what Toronto has dubbed the "Discovery District," a two-square-kilometre chunk of the downtown core, encompassing U of T and four major hospitals. From there, MaRS hopes to act as a network hub across Ontario, with links to research-intensive universities. "None of them," says Evans, "have the critical mass to put it all together on their own."
  • ...3 more annotations...
  • MaRS's primary goal is to get Toronto and the rest of Ontario on the global biotech map. Evans came up with the concept in the late 1990s with Dr. Calvin Stiller, CEO of the labor-sponsored Canadian Medical Discoveries Fund, and Kenneth Knox, a former deputy minister for the Ontario government who's now CEO of MaRS
  • As far as schemes to support fledgling industries go, MaRS is refreshing. To start, it's a nonprofit corporation, not a government program, which will hopefully ensure that it runs more efficiently. The feds and the province of Ontario have each doled out $20 million for MaRS, and Toronto has donated in-kind $4.5 million. More than $12 million has come from a small pool of corporations, including Eli Lilly Canada and MDS, as well as individual donors like Joseph Rotman and Lawrence Bloomberg (who both sit on the MaRS board). U of T pitched in $5 million, and MaRS also did some innovative bond financing to round off the $165 million needed to build Phase I. "It was very important for us to not belong to anybody," says Evans.
  • Now MaRS's challenge is to get the word out. Its posted rate of $26 per square foot is very competitive for prime downtown real estate and is sure to attract attention, especially considering its customized lab space. But MaRS's success won't be measured by a low vacancy rate; getting the right mix of scientists, entrepreneurs and professionals is critical if it plans to commercialize some sustainable businesses. It won't happen overnight--in fact, it may be 10 years before anyone can gauge MaRS's impact. Seems growing a biotech industry isn't quite as easy as growing E. coli in a petri dish.
  • Assunta Krehl on 27 Aug 09
     
    John Evans spearheads the MaRS project which will help to accelerate commercialization for scientific research. The official launch of the MaRS plan will happen on May 12, 2003.
Assunta Krehl

Bootstrapping VC (The Deal Magazine) - 0 views

www.thedeal.com/...ian-provinces-dive-into-vc.php

Canadian Venture Capital Association mars mars centre capital funds investors

shared by Assunta Krehl on 04 Aug 09 - Cached
  • "The size of what Quebec did caught our attention," says CVCA president Gregory Smith from the association's tiny office in Toronto's MaRS Centre, a renovated 1913 hospital now a facility to house tech startups.
  • Assunta Krehl on 04 Aug 09
     
    Bernier is now founder and managing partner of the Teralys Capital Fund, the C$825 million ($730 million) fund-of-funds announced in April by the Quebec government and several partners.
Assunta Krehl

MaRS Innovation appoints president and CEO - University of Toronto -- News@UofT - 0 views

www.news.utoronto.ca/...oints-president-and-ceo-1.html

MaRS Innovation Toronto Discovery District Rafi Hofstein Tim McTiernan The Innovations Group

shared by Assunta Krehl on 15 Jun 09 - Cached
  • MaRS Innovation appoints president and CEO
  • A research commercialization leader from Israel, Dr. Raphael Hofstein, has been named president and CEO of the new MaRS Innovation initiative.
  • MI was created as a single, market-facing commercialization storefront for Toronto's university and health research institutions. Located in the MaRS Discovery District complex, with business development and administrative support from MaRS, MI will advance commercialization through industry partnerships, licensing and company creation. MaRS Innovation (MI) was founded in 2008 with $14.95 million in funding from the Government of Canada's Centres of Excellence for Commercialization and Research (CECR) Programme, matched by $10 million from the research partners. The MI partnership includes U of T, the 10 partner hospitals and health research institutes affiliated with the university, Ryerson University, the Ontario College of Art & Design, BioDisocovery Toronto, the Ontario Institute for Cancer Research and MaRS. Hofstein joins MaRS Innovation from his previous position as president and CEO of Hadasit Ltd., the technology transfer company of the Hadassah Medical Organization in Jerusalem.
  • ...3 more annotations...
  • "MaRS Innovation is a unique global initiative, and I must commend the institutional leaders in Toronto for pulling this innovation powerhouse together to strengthen commercialization output. In my experience, good science is the single most important ingredient for success in this business. Toronto is already known as one of the strongest science cities in the world, and it continues to grow. Leading MaRS Innovation is a wonderful opportunity to do something remarkable."
  • Dr. Tim McTiernan, assistant vice-president (research) and executive director of The Innovations Group (TIG), U of T's research commercialization operation, said Mars Innovation will provide significant benefits to U of T.
  • And he said that MI's role as a resource "is like putting a turbo charger on an engine. Having MI working with us and the other member organizations is a huge step in taking advantage of the enormous potential in the Toronto research community. Commercialization offices acting independently will not be able to manage in nearly as effective a manner as will be possible with the expertise of MaRS Innovation."
  • Assunta Krehl on 15 Jun 09
     
    Dr. Raphael Hofstein named president and CEO of the new MaRS Innovation initiative.
Assunta Krehl

Toronto's $25 million commercialization "engine" celebrates the appointment of its Boar... - 0 views

www.marsdd.com/...ard-of-directors-02062009.html

MaRS Innovation Ilse Treurnicht John Evans Ron Close The Hospital for Sick Children MaRS

shared by Assunta Krehl on 14 Aug 09 - No Cached
  • MaRS Innovation is honoured to announce its permanent Board of Directors, who brings together a remarkable and broad set of experiences and networks to support the development of this dynamic partnership of Toronto research institutions.  Designed to enhance the commercial output of Toronto’s world-leading research cluster, MaRS Innovation is positioned to make a significant contribution to Canada’s innovation economy and the quality of life for Canadians and others around the world.
  • upported by the Government of Canada through the Centres of Excellence in Research and Commercialization (CECR) program, and its member institutions, MaRS Innovation is focused on converting important discoveries into a new generation of products, services and high value jobs. The newly appointed Board of Directors, which includes academic and business leaders from across Canada and the United States, has the targeted expertise to guide MaRS Innovation to deliver on this critical mission.   MaRS Innovation represents a unique collaborative model, which aggregates the exceptional discovery pipeline of 14 leading Toronto academic institutions to build a diversified portfolio of assets, and harness the economic and job creation potential of the best opportunities for Toronto, Ontario and Canada.
  • “MaRS Innovation is privileged to announce a Board of Directors of this caliber and breadth of skill,” said Mary Jo Haddad, Chair of the MaRS Innovation Board and President and CEO of The Hospital for Sick Children. “The collective experience and guidance of these individuals will be critical to developing a collaborative, integrated and agile approach to this transformational organization that will move Canada into its next phase of economic development.”
  • ...2 more annotations...
  • W. Geoffrey Beattie – Deputy Chairman & President, Woodbridge Company Limited, Thomson Reuters Corporation, Toronto Christopher C. Capelli – Vice President, Technology Based Ventures, Office of Technology Commercialization, University of Texas, M.D. Anderson Cancer Center, Houston, TX Ron Close – Information technology entrepreneur, Entrepreneur-in-Residence, MaRS, and Executive Entrepreneur-in-Residence, The Richard Ivey School of Business, The University of Western Ontario, London, ON Nicholas Darby – Formerly Director of Physical Sciences, Corporate Venture Capital, Dow Chemical Company, President, Darby & Associates Consulting LLC, Midland, MI  Mary Jo Haddad – President & CEO, The Hospital for Sick Children, Toronto Jacqueline H.R. Le Saux – Former General Counsel, North America and Corporate Secretary, Patheon, Inc., Toronto David A. Leslie - Chair, Sunnybrook Health Sciences Centre, and Former Chairman & CEO, Ernst & Young, Toronto Michael H. May – President & CEO, Rimon Therapeutics, Toronto Chandra J. Panchal – Founder, President & CEO, Axcelon Biopolymers Corp., Dollard-des-Ormeaux, QC Ilse Treurnicht – CEO, MaRS Discovery District, Toronto Donald A. Wright – President & CEO, The Winnington Capital Group Inc., Toronto
  • MaRS Innovation serves as a business accelerator platform with a single point of entry for industry partners and investors.  It will increase the scale, scope and viability of IP offerings, and the quantity and quality of deal flow from partner institutions.  MaRS Innovation will also facilitate strategic research collaborations with industry partners, strengthen the innovation capacity of Canadian industry through adoption of new technologies from its member institutions, and launch a new generation of robust, high-growth Canadian companies that will become global market leaders.   The quality of the combined discovery pipeline will catalyze and attract sources of risk capital for translational research, market validation, company formation and growth.  “MaRS Innovation represents a unique and timely platform to contribute in a meaningful way to Canada’s knowledge economy, leveraging Toronto’s remarkable research excellence.  The vision and serious commitment of its members to work together to transform our commercialization results, and the support of the Federal Government, made this possible.  The announcement of this outstanding group of leaders to the Board of Directors for MaRS Innovation is an exciting step forward,” said Ilse Treurnicht, MaRS CEO and interim Managing Director of MaRS Innovation.
  • Assunta Krehl on 14 Aug 09
     
    MaRS Innovation announced its permanent Board of Directors. MaRS Innovation is focused on converting important discoveries into a new generation of products, services and high value jobs.
  • Assunta Krehl on 14 Aug 09
     
    MaRS Innovation announced its permanent Board of Directors. MaRS Innovation is focused on converting important discoveries into a new generation of products, services and high value jobs. Feb 6, 2009
Assunta Krehl

Made-to-measure road toll system - Canada's Most Trusted Auto Resource - Wheels.ca - 0 views

www.wheels.ca/...505129

wireless communications Skymeter

shared by Assunta Krehl on 14 Aug 09 - Cached
  • Skymeter Corporation – a high-tech upstart that has perfected "financial-grade" GPS telematics – is being hailed as an innovator that has captured the attention of global giants such as IBM, Cisco and Siemens.
  • Hassan admits while North America may not be ready for road and congestion tolls, governments elsewhere are beating a path to his modest office at the MaRS business incubator at College St and University Ave.
  • While Skymeter is a relative flyweight (the company is estimated to be worth $10 million), it hopes to be the technology provider to large multinationals such as IBM and Siemens in the project tenders.
  • ...1 more annotation...
  • Skymeter is poised to usher in smart metering and – if the execution holds true to the vision – tolls that directly fund roads that are in demand.
  • Assunta Krehl on 14 Aug 09
     
    Skymeter Corporation - a high-tech upstart that has perfected "financial-grade" GPS telematics - is being hailed as an innovator that has captured the attention of global giants such as IBM, Cisco and Siemens. Mention of MaRS as a business incubator. Feb 14, 2009
  • Assunta Krehl on 14 Aug 09
     
    Skymeter Corporation - a high-tech upstart that has perfected "financial-grade" GPS telematics - is being hailed as an innovator that has captured the attention of global giants such as IBM, Cisco and Siemens. Mention of MaRS as a business incubator.
Assunta Krehl

Ever Been To MaRS? - Flickr - 0 views

www.flickr.com/...3420334874

mars

shared by Assunta Krehl on 10 Aug 09 - Cached
  • This building, the old Toronto General Hospital, is now the home of MaRS - a public-private partnership designed to assist research, development, and technology initiatives and related entrepreneurs. The redone space is stunning - an open concept with glass offices looking out into a cavernous main foyer. The exterior, as seen in the photo, is pretty impressive too. Nice to see that they maintained most of the facade despite the fairly extensive internal alterations. 
  • Assunta Krehl on 10 Aug 09
     
    Blog has a photo of the MaRS Centre and briefly mentions about the attractiveness architecture of the building.
  • Assunta Krehl on 10 Aug 09
     
    Blog has a photo of the MaRS Centre and briefly mentions about the attractiveness architecture of the building. April 15, 2009
Assunta Krehl

Go to MaRS - Canadian Newcomers Magazine - 0 views

74.125.77.132/search

stories KCT Clera

shared by Assunta Krehl on 14 Aug 09 - Cached
  • nd development of new ideas. It provides not only office and lab space but also free mentoring assistance to new businesses in science, technology and social innovation. While there are probably no chickens hatching at MaRS, it wouldn't be at all surprising to find a company working on, say, a vaccine for bird flu. Approximately 20 incubator companies are currently housed at MaRS, including Clera Inc. - which is developing treatments for schizophrenia and depression; AXS Biomedical Animations Studio - a company that creates 3D medical animation for biomedical research and other applications; and Kanata Chemical Technologies (KCT), which has had great success developing catalysts for the chemical industry (catalysts speed up chemical reactions without being changed or consumed in those reactions
  • All of the above definitions could apply to the wider innovation community connected with the MaRS Centre. Located in the heart of Toronto's Discovery District - a 2.5 sq. kilometre downtown research district, MaRS is a non-profit environment for the birt
  • KCT founder and president Kamal Abdur-Rashid came to Canada in 1997 with a degree from the University of the West Indies
  • ...5 more annotations...
  • With support from the Mississauga Technology Business Accelerator (MTBA) he started his business, which grew to occupy some state-of-the-art labs at MaRS and is about to take the next step forward by moving its business outside of the protecting and nurturing environment of MaRS. This is the entire purpose of MaRS, which says on its website (www.marsdd.com), "We measure our success through the companies that emerge after receiving help from MaRS." "The resources, the facilities, the training and everything else that MaRS is bringing to the table - we're able to capitalize on that and get off on a very solid footing," says Kamal. Inside the Incubato
  • Whether you're looking for work - or you want to start your own business, MaRS is one of the best places to start your search.
  • Everybody you talk to in the elevator, the hall, the cafeteria - they are all in the science field - so you can network with one another," says Ratheesh. "MaRS does not just provide research space, they are bringing business people, people with money." These are the connections that can turn your idea into a profit-making business that employs many people. This is exactly what MaRS is all about. As they say on their website, "MaRS connects the communities of science, business and capital and fosters collaboration among them." MaRS advisors are able to connect entrepreneurs with private funding opportunities as well as free educational programming and hands-on advisory services. Corporate sponsor CIBC funds an entrepreneurship lecture series, for example. Ratheesh adds, "Patent people are here as well, so if you have patentable technology, you can talk to them." Once you start your business, MaRS offers many supports. "When we had the lab space we had the chemical hood that had to be set up so MaRS came and provided people to set up our hood," explains Ratheesh. "They help us dispose of chemical waste, provide water service, fridge and freezer service - so these are all important. "For smaller companies that have problem buying fridges and freezers, they can use common equipment." MaRS facilities also include lecture theatres, meeting rooms and an auditorium. Growing Cultures Bacteria and tissue cultures aren't the only cultures that thrive in the MaRS environment. It's also a great place for newcomers from every culture to
  • Clera, one of many emerging companies housed in the MaRS incubator.
  • He says, "MaRS is a one-stop shop for job and information seekers. Here we have many companies - so quite a few job opportunities
  • Assunta Krehl on 14 Aug 09
     
    A look at Canadian immigrants who started a business and are incubating at the MaRS Centre. KCT and Clera, MaRS Tenants tell their stories. Jan/Feb 2009
  • Assunta Krehl on 14 Aug 09
     
    A look at Canadian immigrants who started a business and are incubating at the MaRS Centre. KCT and Clera, MaRS Tenants tell their stories.
‹ Previous 21 - 40 of 46 Next ›
Showing 20▼ items per page